[
  {
    "ts": null,
    "headline": "AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients",
    "summary": "AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. Also Read: After Lung Cancer Approval, AstraZeneca’s Imfinzi Goes Under",
    "url": "https://finnhub.io/api/news?id=944a9b13d62e177356b7d6b51277bf97cb6aec319997021aefb71136a3a083dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733944218,
      "headline": "AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients",
      "id": 131924099,
      "image": "https://media.zenfs.com/en/Benzinga/ea26a47393d00466b04b8a525b488c58",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. Also Read: After Lung Cancer Approval, AstraZeneca’s Imfinzi Goes Under",
      "url": "https://finnhub.io/api/news?id=944a9b13d62e177356b7d6b51277bf97cb6aec319997021aefb71136a3a083dd"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=7e3c1f90e450efd0779cccce7cb4cb538a74217bcc68f84e8109f688cfaa06fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733934900,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 131933615,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=7e3c1f90e450efd0779cccce7cb4cb538a74217bcc68f84e8109f688cfaa06fc"
    }
  },
  {
    "ts": null,
    "headline": "LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial",
    "summary": "RAHWAY, N.J., December 11, 2024--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.",
    "url": "https://finnhub.io/api/news?id=68d9779da8961db19fc5d9aff528cdac47459b0bb3f25a45f164040fa9c25e8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733930520,
      "headline": "LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial",
      "id": 131924100,
      "image": "https://media.zenfs.com/en/business-wire.com/19451551137d16ab4d686107f402af0b",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 11, 2024--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.",
      "url": "https://finnhub.io/api/news?id=68d9779da8961db19fc5d9aff528cdac47459b0bb3f25a45f164040fa9c25e8b"
    }
  },
  {
    "ts": null,
    "headline": "Merck and AstraZeneca unveil long-term Lynparza results",
    "summary": "Merck & Co Inc and AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term results from phase three OlympiA trial on the use of Lynparza,...",
    "url": "https://finnhub.io/api/news?id=37d8ca1cba3f68ab96e39cbc4e389cb93da7c7172da6fed6175b19782bee4725",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733928131,
      "headline": "Merck and AstraZeneca unveil long-term Lynparza results",
      "id": 131921515,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc and AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term results from phase three OlympiA trial on the use of Lynparza,...",
      "url": "https://finnhub.io/api/news?id=37d8ca1cba3f68ab96e39cbc4e389cb93da7c7172da6fed6175b19782bee4725"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International",
    "summary": "Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=41a18da5c6adda8ca79fc72c0027db83a2aead36108f18c0f5a49a730e6fc30d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733901300,
      "headline": "The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International",
      "id": 131915533,
      "image": "https://media.zenfs.com/en/zacks.com/30e90ac213ebedcfe9ef1b79c529169c",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=41a18da5c6adda8ca79fc72c0027db83a2aead36108f18c0f5a49a730e6fc30d"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?",
    "summary": "We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other American dividend stocks. The US economy expanded by 2.8% in the third quarter of 2024, as reported in the […]",
    "url": "https://finnhub.io/api/news?id=e70686a79853ed3b8f8c5f0226b24154aca752354470fca6ecf79c9470cd3379",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733892445,
      "headline": "Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?",
      "id": 131915896,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other American dividend stocks. The US economy expanded by 2.8% in the third quarter of 2024, as reported in the […]",
      "url": "https://finnhub.io/api/news?id=e70686a79853ed3b8f8c5f0226b24154aca752354470fca6ecf79c9470cd3379"
    }
  }
]